News

Top 10 Pulmonary Hypertension Stories of 2020

Throughout 2020, Pulmonary Hypertension News brought daily coverage of groundbreaking research, treatment advancements, and clinical trial developments related to pulmonary hypertension (PH). As we anticipate bringing you more PH news this year, we take a look back…

PHA Names New President and CEO, Matt Granato

Matt J. Granato is the newly named president and CEO of the Pulmonary Hypertension Association (PHA), the nonprofit group announced. Granato, who has more than 20 years of experience working in nonprofits and healthcare associations, will assume this office and its duties on Jan. 4. He is the third…

Sotatercept Receives Orphan Drug Designation in Europe

The European Commission has granted orphan drug designation to sotatercept for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications with the potential to substantially improve care for rare diseases — defined as those that affect fewer than five individuals per 10,000…

Adempas Safe in PAH Patients Over Long Term, Real-world Study Shows

Long-term treatment with Bayer’s Adempas (riociguat) was safe and well-tolerated in people with pulmonary arterial hypertension (PAH), according to data from the real-world EXPERT study. These findings from clinical practice were consistent with those reported in previous clinical trials, supporting the therapy’s favorable safety profile. Data from EXPERT…